Drug name - Victoza

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6268343 NOVO NORDISK INC Derivatives of GLP-1 analogs
Aug, 2022

(a month ago)

US8114833 NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(2 years from now)

CN1951965A NOVO NORDISK INC Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN100569798C NOVO NORDISK INC Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1740198A NOVO NORDISK INC Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1232470A NOVO NORDISK INC Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1271086C NOVO NORDISK INC Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1951965B NOVO NORDISK INC Glp-1 Derivatives
Aug, 2017

(5 years ago)

CN1882356B NOVO NORDISK INC For The Production And Used In The Injection Device Is The Best Peptide Formulations Containing Propylene Glycol
Nov, 2024

(2 years from now)

CN1882356A NOVO NORDISK INC In The Production And Injection Device Is The Best Peptide Formulation Contains Propylene Glycol
Nov, 2024

(2 years from now)

IN257402B NOVO NORDISK INC Propylene Glycolcontaining Peptide Formulations
Nov, 2024

(2 years from now)

IN200602771P1 NOVO NORDISK INC Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

EP1840134A3 NOVO NORDISK INC Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1056775B1 NOVO NORDISK INC Glp-1 Derivatives Of Glp-1 And Exendin With Protracted Profile Of Action
Feb, 2019

(3 years ago)

EP1840134B1 NOVO NORDISK INC Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1840134A2 NOVO NORDISK INC Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1056775A1 NOVO NORDISK INC Glp-1 Derivatives Of Glp-1 And Exendin With Protracted Profile Of Action
Feb, 2019

(3 years ago)

EP1060191A1 NOVO NORDISK INC Derivatives Of Glp-1 Analogs
Feb, 2019

(3 years ago)

EP1062240A1 NOVO NORDISK INC N-Terminally Modified Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1061946A1 NOVO NORDISK INC Glp-1 Derivatives With Helix-Content Exceeding 25 %, Forming Partially Structured Micellar-Like Aggregates
Feb, 2019

(3 years ago)

EP1060191B1 NOVO NORDISK INC Derivatives Of Glp-1 Analogs
Feb, 2019

(3 years ago)

EP1061946B1 NOVO NORDISK INC Glp-1 Derivatives With Helix-Content Exceeding 25 %, Forming Partially Structured Micellar-Like Aggregates
Feb, 2019

(3 years ago)

EP1062240B1 NOVO NORDISK INC N-Terminally Modified Glp-1 Derivatives
Feb, 2019

(3 years ago)

EP1061947B1 NOVO NORDISK INC Stabilized Aqueous Glucagon Solutions Comprising Detergents
Mar, 2019

(3 years ago)

EP1061947A1 NOVO NORDISK INC Stabilized Aqueous Glucagon Solutions Comprising Detergents
Mar, 2019

(3 years ago)

EP944648B1 NOVO NORDISK INC Glp-1 Derivatives
Aug, 2022

(a month ago)

EP944648A1 NOVO NORDISK INC Glp-1 Derivatives
Aug, 2022

(a month ago)

EP1687019A2 NOVO NORDISK INC Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

EP1687019B1 NOVO NORDISK INC Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

EP3300721A1 NOVO NORDISK INC Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

EP3300721B1 NOVO NORDISK INC Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices
Nov, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846618

(Pediatric)

NOVO NORDISK INC Stable formulation of modified GLP-1 Dec, 2022

(2 months from now)

US6268343

(Pediatric)

NOVO NORDISK INC Derivatives of GLP-1 analogs Feb, 2023

(4 months from now)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly Jun, 2023

(8 months from now)

US8579869

(Pediatric)

NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly Dec, 2023

(1 year, 2 months from now)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly May, 2024

(1 year, 7 months from now)

US7762994

(Pediatric)

NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly Nov, 2024

(2 years from now)

US8114833

(Pediatric)

NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Feb, 2026

(3 years from now)

US9265893 NOVO NORDISK INC Injection button Sep, 2032

(9 years from now)

US9265893

(Pediatric)

NOVO NORDISK INC Injection button Mar, 2033

(10 years from now)

US9968659 NOVO NORDISK INC Liraglutide in cardiovascular conditions Jan, 2037

(14 years from now)

US9968659

(Pediatric)

NOVO NORDISK INC Liraglutide in cardiovascular conditions Jul, 2037

(14 years from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administering liraglutide

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.